Treatment of Newly Diagnosed POEMS Syndrome: Bortezomib or Lenalidomide? Experience from Two Countries


Creative Commons License

ÖZMEN İBİŞ D., Autore F., Özkan T., Musayeva G., Birsin Z., Mannina D., ...Daha Fazla

Mediterranean Journal of Hematology and Infectious Diseases, cilt.18, sa.1, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 1
  • Basım Tarihi: 2026
  • Doi Numarası: 10.4084/mjhid.2026.084
  • Dergi Adı: Mediterranean Journal of Hematology and Infectious Diseases
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Directory of Open Access Journals, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
  • Anahtar Kelimeler: Bayesian analysis, Bortezomib, Lenalidomide, POEMS syndrome
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Background: POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes) syndrome is a rare plasma cell disorder where treatment selection remains largely empirical. Lenalidomide-based regimens are generally preferred in the first line due to concerns about bortezomib-induced neurotoxicity, despite limited comparative evidence. We aimed to directly compare the real-world efficacy and safety of first-line bortezomib-versus lenalidomide-based regimens. Methods: In this retrospective multicenter cohort, 26 newly diagnosed POEMS patients between 2005 and 2024 from Türkiye and Italy were included. Nine patients received bortezomib-based therapy and 17 received lenalidomide–dexamethasone. The primary endpoint was overall survival (OS); the secondary endpoint was hematologic response. Results: Bortezomib-based therapy achieved significantly higher rates of deep response (≥VGPR, defined as complete response or very good partial response) compared with lenalidomide (88.9% vs 37.5%; p = 0.013). Despite a higher prevalence of baseline symptomatic neuropathy in the bortezomib group (77.8% vs 29.4%; p = 0.038), no treatment-emergent worsening of neuropathy was observed. Model-based 5-year overall survival was 86.6% with bortezomib and 80.7% with lenalidomide (time ratio [TR] 0.61, 95% CrI 0.04–6.78), indicating no survival difference between the two strategies, with similar autologous transplantation rates and toxicity profiles. Conclusion: In this multicenter real-world cohort, bortezomib-based first-line therapy was associated with markedly deeper hematologic responses without excess neurotoxicity, and no survival difference could be demonstrated in this small cohort. These findings suggest that bortezomib-based therapy may be an effective upfront option in selected patients and support re-evaluating first-line strategies in prospective studies.